Overview

A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

Status:
NOT_YET_RECRUITING

Trial end date:
2027-10-20

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to evaluate the safety and tolerability of the continuation of sotorasib with or without panitumumab and/or other anti-cancer therapies in participants continuing to derive benefit in Amgen-sponsored protocols.

Phase:

PHASE2

Details

Lead Sponsor:

Amgen

Treatments:

Panitumumab
sotorasib